Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Finland joins Denmark and Sweden to pause giving Moderna Inc's (NASDAQ: MRNA) COVID-19 shots to men under the age of 30 due to the risk of heart inflammation. Related:   Sweden, Denmark Pause Use Of Moderna COVID-19 Shot In Younger Individuals: What You Need To Know.

After Sweden, Denmark Now Finland Stops Use of Moderna COVID-19 Jab In Young People: Report

Denmark, Finland, and Sweden this week said they are limiting use of Moderna Inc.'s MRNA, +2.84% COVID-19 shot over concerns about rare cases of myocarditis and pericarditis in younger people who have received the vaccine. Each country has a different policy; for example, Finland is no longer offering the Moderna shot to men who are younger than 30, according to media reports.

Three Nordic countries halt use of Moderna's COVID-19 vaccine in younger individuals

Moderna Inc (NASDAQ: MRNA) plans to invest about $500 million to build a factory in Africa to make up to 500 million doses of mRNA vaccines at 50 µg dose level each year. Moderna's proposed site will also include bottling and packaging capabilities.

Moderna To Build mRNA Vaccine Factory In Africa

AstraZeneca

Johnson & Johnson

Novavax

Pfizer

It'll likely push the revenue of vaccine victors even further.

What Do Mix-and-Match Doses Mean for Vaccine Stocks?

Biogen

Three Motley Fool contributors think these biotech stocks should be big winners.

3 Biotech Stocks That Could Make You Richer in October and Beyond

Marathon Digital Holdings

Workhorse Group

These innovative companies could deliver jaw-dropping sales growth by 2023.

3 Lightning-Quick Growth Stocks Expected to Increase Sales 1,334% to 22,562% in 3 Years

Amid global criticism over a lack of vaccine availabilty in developing nations, Moderna on Thursday announced it will build a “state-of-the-art” mRNA facility in Africa, aimed at producing 500 million doses of vaccines a year.

Moderna to invest $500 million in ‘state-of-the-art' mRNA vaccine factory in Africa

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to build state-of-the-art mRNA facility in Africa to manufacture up to 500 million doses per year.

Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year

Moderna (MRNA) gets authorization for the third dose of its COVID-19 vaccine, Spikevax, for use in immunocompromised individuals in Europe.

Moderna (MRNA) Gets EMA Authorization for SpikeVax Third Dose

On Wednesday, Moderna Inc. (NASDAQ:MRNA) shares plunged more than 6% after Sweden and Denmark paused the company's covid vaccine use for younger age groups. Sweden's health agency said it is pausing Moderna's covid vaccine use for people born in 1991 and later.

Should you sell Moderna stock as Sweden, Denmark pause covid vaccine use?

The vaccine maker could lose a key portion of its addressable market.

Here's Why Moderna Stock Dropped Today

Moderna Inc (NASDAQ: MRNA) stock fell on the back of Sweden, pausing use of its COVID-19 vaccine, Reuters reported citing reports of possible rare side effects such as myocarditis. The Swedish health agency said that the country would stop using Moderna's shot for people born in 1991 and later.

Sweden, Denmark Pause Use Of Moderna COVID-19 Shot In Younger Individuals: What You Need To Know

Expect to see data this month from several clinical trials that are trying to establish if “mixing and matching” different COVID-19 vaccines is safe and effective or if it's better to get the same booster as the one used in the primary series of shots.

Allowing people to mix COVID-19 vaccines could cut into Pfizer and Moderna's revenue next year

Investors worry a rival's COVID-19 pill will hurt vaccine sales.

Moderna Is Down 12%. Is It Time to Buy?

Sweden's health agency cited an apparent increase in cases of myocarditis and pericarditis, but highlighted the risk of being affected was very small.

Sweden Halts Moderna Vaccine For Young People Over Possible Rare Side Effects

Moderna stock (NASDAQ: MRNA) declined by about 20% over the last week (five trading days) considerably underperforming the broader S&P 500 which was down by about 3% over the same period. There are a couple of recent developments that have hurt Moderna and Covid-19 vaccine stocks in general.

Moderna Stock Dropped 20% Last Week. Is It Worth A Look?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces the launch of global fellowship program for young researchers exploring mRNA medicines.

Moderna Announces the Launch of Global Fellowship Program for Young Researchers Exploring mRNA Medicines

One is a market leader. The other has a big catalyst ahead.

Better COVID Stock: Moderna vs. Novavax

Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Moderna (MRNA) is Poised to Beat Earnings Estimates Again

The European Medicines Agency (EMA) has authorized a third dose of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine for immunocompromised people. Related Link:   After Pfizer, Now Moderna Touts Data Supporting COVID-19 Booster Dose.

Moderna's COVID-19 Booster Ok'd In Europe For Immunocompromised

Moderna, Inc. (MRNA) Presents at Chardan 5th Annual Genetic Medicines Conference (Transcript)

Shares of Moderna Inc. MRNA, +2.66% gained 1.2% in trading on Tuesday after the company announced that the European Medicines Agency authorized a third dose of its COVID-19 vaccine for people who are severely immunocompromised. The authorization applies to those who are least 12 years old who have waited at least 28 days since getting their second dose of the vaccine.

E.U. authorizes third dose of Moderna's COVID-19 vaccine for the immunocompromised

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces European Medicines Agency authorizes third dose of COVID-19 vaccine for immunocompromised individuals aged 12 years and older.

Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older

BioNTech SE

These vaccine stocks are now cheaper due to investors' reaction to Merck's COVID-19 pill data.

Does the Sell-Off of BioNTech and Moderna Stocks Present a Buying Opportunity?

The Public Health Agency of Canada said on Friday evening Moderna Inc.'s (NASDAQ:MRNA) covid-19 vaccine triggered a higher rate of heart inflammations after administering the second dose. The agency also said Pfizer Inc. (NYSE:PFE) and BionTech's covid vaccine had fewer cases of heart inflammation.

News for Moderna Stock (MRNA)